Non Hodgkin Lymphoma News and Research

RSS
MicroRNA controls tumor cell proliferation in most aggressive large B-cell lymphoma

MicroRNA controls tumor cell proliferation in most aggressive large B-cell lymphoma

Researchers launch clinical trials to test novel cellular-immunotherapy to treat three types of blood cancer

Researchers launch clinical trials to test novel cellular-immunotherapy to treat three types of blood cancer

Higher body weight, taller stature during adolescence increase NHL risk

Higher body weight, taller stature during adolescence increase NHL risk

New study examines single 'transformer' proteins involved in cancer

New study examines single 'transformer' proteins involved in cancer

Innovative Phase II trial evaluates effectiveness of diabetes medication for lymphoma

Innovative Phase II trial evaluates effectiveness of diabetes medication for lymphoma

New approaches to treating leukemia, lymphoma and myeloma

New approaches to treating leukemia, lymphoma and myeloma

Experimental gene therapy may improve health outcomes for patients with some forms of blood disorders

Experimental gene therapy may improve health outcomes for patients with some forms of blood disorders

Many European hospitals fail to routinely test people at risk of HIV infection

Many European hospitals fail to routinely test people at risk of HIV infection

Patients with kidney failure at increased risk of developing different types of cancer

Patients with kidney failure at increased risk of developing different types of cancer

Drug combination produces long-term responses in patients with mantle cell lymphoma

Drug combination produces long-term responses in patients with mantle cell lymphoma

Bacterium that causes Q fever associated with increased risk of lymphoma

Bacterium that causes Q fever associated with increased risk of lymphoma

EUROCARE 5 study shows large variations in blood cancer patients' survival in Europe

EUROCARE 5 study shows large variations in blood cancer patients' survival in Europe

Investigational topical drug shows promise in patients with early stage cutaneous T cell lymphoma

Investigational topical drug shows promise in patients with early stage cutaneous T cell lymphoma

Hetero Group launches biosimilar 'Rituximab' under brand name MABALL in India

Hetero Group launches biosimilar 'Rituximab' under brand name MABALL in India

Study examines link between use of diabetes drug pioglitazone and increased risk of bladder cancer

Study examines link between use of diabetes drug pioglitazone and increased risk of bladder cancer

Mayo Clinic awarded $11 million NCI grant to study survivorship in patients with non-Hodgkin lymphoma

Mayo Clinic awarded $11 million NCI grant to study survivorship in patients with non-Hodgkin lymphoma

Two years may be a more practical survival goal for patients with follicular lymphoma

Two years may be a more practical survival goal for patients with follicular lymphoma

Novartis CTL019 CAR T cell therapy demonstrates potential to treat B-cell lymphomas

Novartis CTL019 CAR T cell therapy demonstrates potential to treat B-cell lymphomas

Study: New cases of cancer rising globally, but death rates falling in many countries

Study: New cases of cancer rising globally, but death rates falling in many countries

Combination of contraceptive and cholesterol-lowering drugs kills cancer cells in a new way

Combination of contraceptive and cholesterol-lowering drugs kills cancer cells in a new way

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.